1. tonghua dongbao:
The possession of recombinant human insulin products has filled the gap in China. The company is a large pharmaceutical enterprise producing Chinese and western medicines and biological medicines, a national key high-tech enterprise, and has become one of the large-scale human insulin production bases in the world. The leading products are recombinant human insulin bulk drug (obtained GMP certificate in China), recombinant human insulin injection (Ganshulin R, Ganshulin N, Ganshushuang 30R, 40R, 50R, etc. ), Dongbao pen, and "Tonghua" brand wine.
Insulin bibcock,165438+1October 2nd news, tonghua dongbao's share price rose 9.36% in 7 days, the latest news 12 16 yuan, with a turnover of 206 million yuan.
2. Li Gan Pharmaceutical:
Insulin lispro injection has been registered in Lebanon.
Insulin faucet, 165438+1October 2, Li Gan Pharmaceutical 14 reported16, and its share price was 65. 19 yuan, down 1.94%. In three days, its share price fell by 0.75%, with a total market value of 37 1.
3. Yifan Medicine: Domestic sales of recombinant human insulin increased compared with last year.
4. Yiling Pharmaceutical: The company has successfully listed Jinlida Granule, a patented new drug for the treatment of type II diabetes. Jinlida Granule can obviously reduce blood sugar, improve glucose tolerance, obviously increase the number of insulin receptors in hepatocyte membrane, reduce blood sugar and glycosylated hemoglobin of patients, regulate blood lipid, increase insulin sensitivity index and improve clinical symptoms.
5. Sannuo Bio: The company has developed a mobile phone blood glucose meter, which is expected to be listed early next year; Using barcode-free technology can obviously reduce the dose error of insulin; A gold electrode test paper was developed. Gold electrode improves the stability of enzyme reagent and has better accuracy.
6. Fosun Pharma: Jiangsu Wanbang, which holds 95.2% of the shares, is the only animal insulin raw material base in China, and Sinopharm Holdings (1099. HK), holding 32.05%, is the largest drug distributor in China.
7. Haizheng Pharmaceutical Co., Ltd.: The company started the third phase clinical study of insulin glargine and insulin aspart; On the evening of February 28th, 20 17, 17, the company obtained the clinical approval of the company's Degu insulin bulk drug variety and its preparation variety Degu insulin injection from the US Food and Drug Administration. Degu insulin injection is a long-acting insulin, which is used for diabetic patients who need insulin treatment. Global sales in 20 16 exceeded 640 million USD. In China, no other similar products have obtained clinical trial license and marketing license.